Ongoing 5-year+ survival after multiple metastasectomies, followed by CAPOX plus bevacizumab, for metastatic colorectal cancer

Ongoing 5-year+ survival after multiple metastasectomies, followed by CAPOX plus bevacizumab, for metastatic colorectal cancer

Abstract Background Advancements in chemotherapy for metastatic colorectal cancer (mCRC) have improved long-term outcomes, and median survival currently exceeds 30 months. The recommended treatment for mCRC is multidisciplinary, including a combination of surgical resection and chemotherapy. In this...

Full description

Bibliographic Details
Main Authors: Kozue Matsuishi, Yuji Miyamoto, Yukiharu Hiyoshi, Ryuma Tokunaga, Katsunori Imai, Hiromitsu Hayashi, Yoichi Yamashita, Naoya Yoshida, Hideo Baba
Format: Article
Language:English
Published: SpringerOpen 2020-06-01
Series:Surgical Case Reports
Subjects:
Metastatic colorectal cancer
Metastasectomy
Chemotherapy
Long-term survival
Online Access:http://link.springer.com/article/10.1186/s40792-020-00913-x

Internet

http://link.springer.com/article/10.1186/s40792-020-00913-x

Similar Items